|
Feb 24
|
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
|
|
Feb 17
|
TAK vs. DSNKY: Which Stock Is the Better Value Option?
|
|
Feb 15
|
Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?
|
|
Feb 14
|
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
|
|
Feb 12
|
BBI announces $31m facility for Shire to enhance asset finance
|
|
Feb 10
|
Are orexins the next golden child of neuroscience?
|